Clinical Trial Update: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial at MD Anderson evaluating a combination of acalabrutinib, lenalidomide, and rituximab for CD20-positive follicular lymphoma at stages III-IV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Acalabrutinib (Calquence) (acalabrutinib)
• Lenalidomide (Revlimid) (lenalidomide)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING